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National Cholesterol Awareness Month
The ATF6-Met[67]Val Substitution Is Associated With
Increased Plasma Cholesterol Levels
Steven J.R. Meex, Daphna Weissglas-Volkov, Carla J.H. van der Kallen, Donna J. Thuerauf,
Marleen M.J. van Greevenbroek, Casper G. Schalkwijk, Coen D.A. Stehouwer, Edith J.M. Feskens,
Lonneke Heldens, Torik A. Ayoubi, Marten H. Hofker, Bradly G. Wouters, Robert Vlietinck,
Janet S. Sinsheimer, Marja-Riitta Taskinen, Johanna Kuusisto, Markku Laakso, Tjerk W.A. de Bruin,
Pa¨ivi Pajukanta, Christopher C. Glembotski
Objective—Activating transcription factor 6 (ATF6) is a sensor of the endoplasmic reticulum stress response and regulates
expression of several key lipogenic genes. We used a 2-stage design to investigate whether ATF6 polymorphisms are
associated with lipids in subjects at increased risk for cardiovascular disease (CVD).
Methods and Results—In stage 1, 13 tag-SNPs were tested for association in Dutch samples ascertained for familial
combined hyperlipidemia (FCHL) or increased risk for CVD (CVR). In stage 2, we further investigated the SNP with
the strongest association from stage 1, a Methionine/Valine substitution at amino-acid 67, in Finnish FCHL families and
in subjects with CVR from METSIM, a Finnish population-based cohort. The combined analysis of both stages reached
region-wide significance (P9104), but this association was not seen in the entire METSIM cohort. Our functional
analysis demonstrated that Valine at position 67 augments ATF6 protein and its targets Grp78 and Grp94 as well as
increases luciferase expression through Grp78 promoter.
Conclusions—A common nonsynonymous variant in ATF6 increases ATF6 protein levels and is associated with
cholesterol levels in subjects at increased risk for CVD, but this association was not seen in a population-based
cohort. Further replication is needed to confirm the role of this variant in lipids. (Arterioscler Thromb Vasc Biol.
2009;29:1322-1327.)
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High serum total cholesterol (TC), low-density lipopro-tein cholesterol (LDL-C), and apolipoprotein B (apoB)
are major risk factors for cardiovascular disease (CVD).
Cholesterol levels are tightly regulated through a feedback
pathway from the endoplasmic reticulum (ER) to the nucl-
eus.1 Sterol regulatory element binding protein 2 (SREBP2),
an ER resident transcription-factor, has a central role in
cellular cholesterol homeostasis.2 In response to cholesterol
demand the active domain of SREBP2 is released to the
cytoplasm and migrates to the nucleus where it binds sterol
response element (SRE) sequences in the promoter of target
genes, such as the LDL receptor gene.2
ATF6 is also an ER membrane-bound transcription-factor
and a major regulator of the unfolded protein response
(UPR).3 The UPR is an evolutionary conserved stress-
signaling pathway from the ER to the nucleus. Various
stressful conditions, eg, nutrient deprivation, oxidative stress,
high and low glucose concentrations, viral infections, obesity,
and increased synthesis of secretory proteins, lead to accu-
mulation of unfolded proteins and trigger the UPR.4,5 Besides
a role for ATF6 in the UPR, lipogenic properties have been
ascribed to ATF6, and crosstalk with the SREBP2 pathway
has been demonstrated.6 There is growing evidence that
ATF6-mediated attenuation of SREBP2 fine-tunes the cho-
lesterol biosynthetic pathway in cells under conditions of ER
stress.6 More specifically, Zeng et al demonstrated in vitro
that changes in glucose levels influences lipogenesis via
ATF6-mediated inhibition of SREBP2.6 Additional parallel
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pathways through which ATF6 could modulate cholesterol
homeostasis may exist, suggested by the presence of ATF6-
binding elements in the promoter of the apoB gene.7
We investigated whether genetic variation in the ATF6
gene is associated with plasma TC, LDL-C, and apoB levels,
and whether it contributes to the complex genetic background
of CVD. We used a 2-stage design. In stage 1, we performed
genotyping of tag-SNPs in the ATF6 gene region to test for
association in Dutch samples ascertained for familial com-
bined hyperlipidemia (FCHL) or increased risk for CVD
(CVR). An amino-acid substitution (methionine[67]valine)
with the strongest evidence of association was further inves-
tigated in stage 2 study samples. We also functionally
demonstrated that this variant augments ATF6 protein levels
and its downstream targets.
Methods
For complete description of the Methods, please see the online
supplemental material available at http://atvb.ahajournals.org.
Study Participants
The study design was approved by the ethics committees of the
participating centers, and all subjects gave written informed consent.
Stage 1 study samples consisted of Sample 1 (Dutch CVR) with a
total of 393 unrelated subjects at increased risk for CVD, ie, age 40
to 70 years and either hypertension (HT), or body mass index (BMI)
25 kg/m2 from the Cohort study of Diabetes and Atherosclerosis
Maastricht,8 and Sample 2 (Dutch FCHL) with a total of 195
unrelated probands and spouses from families with FCHL.9
Stage 2 study samples consisted of Sample 3 (Finnish FCHL) with
715 individuals from 61 Finnish FCHL families,9 and Sample 4
(Finnish CVR) with 1371 subjects with CVR selected from 5112
male subjects in the ongoing Finnish population-based cohort,
METSIM (METabolic Syndrome In Men),9 using the same ascer-
tainment criteria as in Sample 1. All of these study samples are
described in detail in the supplemental Methods.
Statistical Analyses
Association analyses with continuous traits were performed using linear
regression for the genotypic model. The genotypic test is a 2 degrees of
freedom test of an additive (ˆ add) and a dominance-deviation (ˆ dev)
effect. The ˆ dev coefficient reflects a deviation from an additive effect.
A recessive character is suggested when the sign of ˆ dev is opposite of
ˆ add, and a dominant character is suggested when the signs of both
coefficients are in the same direction. A full recessive or dominant
model is observed when the magnitude of the effects is equal
ˆdevˆadd. To avoid violating the assumptions of the test
statistics, we estimated empirical probability values in the combined
analysis of Sample 1 and 2 by combining the 2 statistics from 20 000
random permutations of each sample.9 Association analysis in families
(Sample 3) was performed with the genotypic model of the family-based
association test (FBAT) software.10 The combined analysis of stage 1
and 2 and the meta-analysis of stage 1, Sample 3 and the METSIM
cohort were performed using Fisher method11 for combining probability
value, as described in the supplemental Methods.
Cell Studies
Primary preadipocytes were isolated from subcutaneous adipose tissue
from 11 subjects who underwent fat biopsies. HeLa cells
were used for transfection experiments with the following pla-
smids: Cytomegalovirus-galactosidase; Flag-ATF6-(1–373[67]-
Methionine); Flag-ATF6-(1–373[67]-Valine); Flag-ATF6-(1–373[67]-
Leucine); Grp78 promotor(284–221)-Luciferase, and pGL2p.
Reporter assays included luciferase and -galactosidase assays.
Western blot experiments were done using specific antisera against
ATF6, FLAG, KDEL (Grp78 and Grp94), actin, and GAPDH.
Results
ATF6 Protein Levels Correlate With Plasma
Lipid Levels
We investigated the potential role of the ATF6 gene in
hyperlipidemia by first evaluating the relation between basal
ATF6 levels in cultured human primary preadipocytes and
plasma TC, LDL-C, and apoB levels. We observed a signif-
icant positive correlation between ATF6 levels in vitro and
plasma TC, LDL-C, and apoB levels of the corresponding
subjects (r0.65, P0.032; r0.72, P0.018; and r0.76,
P0.006, respectively; supplemental Figure 1).
Stage 1 Association Analysis
We used a 2-stage design to investigate whether variants
within the ATF6 gene are associated with lipid levels in
subjects at increased risk to develop CVD. In stage 1,
tag-SNPs selected to capture the common genetic variation in
ATF6 were investigated in 2 independent Dutch samples
comprising 393 individuals with increased CVR (Sample 1),
and 195 unrelated FCHL probands and their spouses (Sample
2). In stage 2, the strongest signal was further investigated in
2 Finnish studies: 715 subjects from 61 FCHL families
(Sample 3) and in 1371 subjects with CVR (Sample 4) from
the METSIM cohort. Finally, a combined analysis of the 2
stages was performed to reach a region-wide significance.
Clinical characteristics of the study samples are shown in
supplemental Table 1.
In stage 1, we tested a total of 13 SNPs for association with
TC, LDL-C, and apoB levels using multivariate linear regression
for the genotypic model. (The most significant association was
observed for SNP3 (rs1058405) with TC (P0.009, bdev0.2
to 0.3 and badd0.2 to 0.3), LDL-C (P0.008, bdev0.2 to
0.3 and badd0.2) and apoB (P0.002, bdev0.3 and
badd0.3) (Table 1 and Figure 1). The distributions of TC,
LDL-C, and apoB between the genotype groups suggest a
recessive effect for SNP3, which is also demonstrated by the
equal magnitude and opposite sign of the additive and
dominance-deviation effects. SNP8 and SNP11 were associated
with probability values 0.05 (supplemental Table 1 and sup-
plemental Figure 1) but only SNP3 resulted in probability values
0.05 for all traits. We confirmed that the direction of the
association is the same in both Sample 1 and 2 for all SNPs with
probability value 0.05, as the 2 statistics could go in either
direction. Furthermore, it should be noted that SNP3 is in high
LD with SNP8 (r20.7) and in low LD with SNP11 (r20.2).
Next, we used an imputation-based regression method to
extend our association analysis to nontagged SNPs in the
ATF6 region (supplemental Methods). Furthermore, as we
test for association with all common SNPs (MAF 5%) in
the region using a Bayesian-regression approach, we can
statistically assess which SNP (tagged or nontagged) most
likely affects the traits. We obtained the strongest evidence of
association for SNP3 (ie, the largest estimated Bayes Factor
[BF]) for all the traits (Figure 1). The BF we observed for
apoB (BF1.03) can be considered as strong evidence of
association, and the ones for LDL-C (BF0.77) and TC
(BF0.6) as substantial evidence of association. Taken to-
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gether, these data suggest that in Stage 1, SNP3 is the best
regional-candidate for affecting plasma lipid levels.
SNP3 is a coding variant that translates into the
Methionine[67]Valine amino-acid substitution (supplemental
Figure 2B). According to the dbSNP-database SNP3 is
possibly a triallelic variant (A-G-T 3Met-Val-Leu). How-
ever, the leucine variant is most likely a sequencing error as
it was originally identified in a sample size of 4 individuals
with validation status unknown. Furthermore, we did not
observe the leucine variant in 200 subjects of Sample 1 that
we specifically screened using an allele-specific primer for it.
Stage 1 and 2 Association Analysis
SNP3 that provided a probability value 0.05 for all traits in
the stage 1 analysis was tested in a combined analysis of stage
1 and 2. We analyzed the stage 2 samples using the same
genotypic model as in stage 1 and performed a combined
analysis of the 2 stages using Fisher method11 for combining
probability values weighted by the sample size. This analysis
included a total of 2674 subjects at increased risk to develop
CVD. We observed a significant association between SNP3
and TC (P9104), LDL-C (P0.007), and apoB
(P0.005) levels (Table 2). Similar to the results obtained in
the stage 1 samples, higher lipid levels were also observed
with the Val allele in the stage 2 samples (Table 2). In the
FCHL families (Sample 3), both the lipid genotypic mean
values and the Z-scores for the homozygote rare group (all
ZV/V 1.7) suggest a recessive effect for SNP3, similar to
Samples 1 and 2 (Table 2). However, an additive effect could
not be rejected in the CVR sample selected from the
METSIM cohort (Sample 4), as none of the ˆ dev terms where
significantly different from zero (Table 2). The association
between SNP3 and TC levels is region-wide significant, as it
surpasses the Bonferroni correction for 13 SNPs tested in
Table 1. Association of Met67Val Substitution (SNP3) in Stage I
Trait Met67Val
Sample1 Dutch CVR Sample2 Dutch FCHL
Stage I
P‡n384 ˆ*add (SE) ˆ*dev (SE) R
2† n181 ˆ*add (SE) ˆ*dev (SE) R
2†
TC, mmol/L Val/Val 5.55	0.15 6.72	0.29
Met/Val 5.20	0.07 0.19 (0.9) 0.21 (0.12) 1.20% 5.90	0.17 0.28 (0.11) 0.33 (0.17)§ 3.64% 0.009
Met/Met 5.22	0.07 5.96	0.13
LDL-C, mmol/L Val/Val 3.72	0.14 4.43	0.26
Met/Val 3.28	0.06 0.23 (0.9) 0.30 (0.12)§ 2.01% 3.94	0.15 0.21 (0.11) 0.20 (0.17) 2.03% 0.008
Met/Met 3.34	0.06 3.90	0.12
ApoB, g/L Val/Val 1.24	0.04 1.31	0.07
Met/Val 1.10	0.02 0.25 (0.9) 0.33 (0.12)§ 2.45% 1.11	0.04 0.31 (0.12) 0.32 (0.17) 4.16% 0.002
Met/Met 1.12	0.02 1.11	0.03
Trait values represent the marginal mean evaluated at the average age and sex	SEM.
*ˆadd, indicates the standardized beta coefficients per each copy of the rare allele (additive term) and ˆdev for the dominance-deviation term.
†R2 indicates the proportion of variance explained by the genotypic model.
‡The P values represent the results of the combined analysis of Sample 1 and 2, as described in Methods.
§P0.05 for the significance of deviation from an additive model (ˆdev 
0).
P0.1 for the significance of deviation from an additive model.
Figure 1. Association results of stage 1. Filled
symbols represent the log10 of the probability
values obtained from linear regression test for the
genotypic model. The open symbols represent the
log10 of the probability values obtained from
Bayesian regression test with SNP imputation. The
dashed lines indicates P0.05. The location of the
SNPs is shown in relation to the gene structure of
ATF6 and its adjacent genes.
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stage 1 with 3 traits, as well as 6 additional tests performed in
stage 2 (Adjusted probability value 0.0009450.04). How-
ever, it should be noted that as we tested 3 correlated traits
(average correlation0.85) the Bonferroni correction for
multiple testing, that presumes that tests are independent, is
conservative for our analyses.
Meta-Analysis of SNP3 in a
Population-Based Cohort
As we obtained a region-wide significant association between
SNP3 and plasma TC levels, we also included all available
subjects of the METSIM cohort (ie, CVR and non-CVR) in a
meta-analysis of all samples weighted by the proportion of the
sample size. We did not observe significant associations for TC
in meta-analysis of all subjects (n5812, 24.42, P0.62).
However, as we excluded subjects with T2DM from our study
(Stage 1 and 2) we also performed the meta-analysis while
excluding subjects with T2DM or family history of T2DM from
METSIM. The subjects with family history of T2DM also
exhibit impaired glucose homeostasis, as shown in supplemental
Table 3. We observed a significant association between SNP3
and TC levels (n3471, 218.09, P0.006), suggesting that
the effect of SNP3 may be different between individuals with
and without T2DM and history of T2DM.
Furthermore, the effect of SNP3 was more pronounced in the
stage 1 and 2 analysis that included subjects from METSIM with
CVR (Sample 4; Table 2). To further investigate this relationship
between SNP3, T2DM, and CVR, we examined the effect of
their multiplicative interaction on serum TC levels (supplemen-
tal Methods). We observed that plasma TC levels are signifi-
cantly affected by the interaction of SNP3 and T2DM or fam-
ily history of T2DM (standardizedˆgr0.12 [SE0.05],
P0.01), whereas an opposite direction of interaction was
observed between SNP3 and CVR on serum TC levels (stan-
dardized ˆgr0.10 [SE0.05], P0.03). These data suggest
opposite effects for the Val variant on TC levels between
individuals with T2DM and CVR, with a decreasing effect in
subjects with T2DM or family history of T2DM and an
increasing effect in subjects with CVR.
Functional Characterization of the
Methionine[67]Valine Variant
The Met[67]Val substitution is located in the transcription
activation domain (TAD) of ATF6, more specifically in the
VN8-like region (amino-acid 61 to 68), which is critical for
transcription activity and degradation of ATF6 (supplemental
Figure 2).12 We observed that this amino acid substitution
was computationally predicted to be damaging to the protein
(PSIC score2.08) based on phylogenetic and structural
information (PolyPhen server tool).13 To explore the possi-
bility that the Met[67]Val polymorphism alters the protein
function, we assessed the effect of amino acid substitution at
position 67 on the protein levels and transcriptional activity
of ATF6 in vitro. Although the Leucine-variant is probably a
sequencing error, we also tested it functionally. Accordingly,
we prepared 3 constructs of FLAG-tagged ATF6(1–373) that
mimic active ATF6 generated by ER stress. These 3 con-
structs only varied in amino acid 67. We tested the 3
constructs in HeLa cells by assaying for luciferase expression
through the GRP78 promoter. The constructs, FLAG-
ATF6(1–373)-[67]-valine and FLAG-ATF6(1–373)-[67]-
leucine had significantly higher luciferase activity than the
Met allele construct (1.4- and 2.5-fold change, respectively;
Figure 2). We also compared the protein levels of endogenous
Grp78 and Grp94, which are direct targets of ATF6, in cells
transfected with FLAG-ATF6 constructs. In agreement with
the results from the luciferase assay, the levels of Grp78 and
Grp94 were significantly higher in cells transfected with
FLAG-ATF6(1–373)-[67]-valine and FLAG-ATF6(1–373)-
[67]-leucine, than those transfected with the Met allele
construct (Figure 3A and 3B). Furthermore, FLAG-ATF6
levels were also increased, suggesting a gain-of-function
substitution. Taken together, these functional data demon-
strate that this variant augments ATF6 protein levels and its
downstream transcriptional targets.
Table 2. Association of Met67Val Substitution (SNP3) in Stage I and II
Trait Met67Val
Sample 3 Finnish FCHL Sample 4 Finnish CVR
Stage III
P§n715 Z*V/V Z*M/V R
2† n1371 ˆ‡add (SE) ˆ‡dev (SE) R
2†
TC, mmol/L Val/Val 6.47	0.23 5.61	0.09
Met/Val 5.96	0.11 1.78 1.68 2.37% 5.56	0.04 0.09 (0.05) 0.05 (0.06) 0.54% 0.0009
Met/Met 6.15	0.12 5.43	0.04
LDL-C, mmol/L Val/Val 4.22	0.20 3.60	0.08
Met/Val 3.82	0.10 2.07 1.71 2.34% 3.57	0.04 0.07 (0.05) 0.04 (0.06) 0.32% 0.0072
Met/Met 3.99	0.10 3.48	0.03
ApoB, g/L Val/Val 1.32	0.07 1.10	0.03
Met/Val 1.11	0.03 2.32 1.32 3.03% 1.12	0.01 0.03 (0.05) 0.08 (0.07) 0.28% 0.0049
Met/Met 1.13	0.03 1.09	0.01
Trait values represent the marginal mean evaluated at the average age and sex	SEM.
*ZV/V, indicates the Z value obtained from the FBAT genotypic model test for the Val/Val genotype and ZM/V for the Met/Val genotype.
†R2 indicates the proportion of variance explained by the genotypic model.
‡ˆadd, indicates the standardized beta coefficients per each copy of the rare allele (additive term) and ˆdev for the dominance-deviation term.
§The P values represent the results of the combined analysis of stage 1 and 2, as described in Methods.
P0.1 for the significance of deviation from an additive model.
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Discussion
Our 2-stage association analysis of tag-SNPs in the ATF6
gene revealed a region-wide significant association between
the Met[67]Val amino-acid substitution and increased TC
levels in samples ascertained for FCHL and risk factors for
CVD. Furthermore, we also functionally demonstrate that the
Met[67]Val substitution augments ATF6 levels and its down-
stream transcriptional targets. These findings are also sup-
ported by a strong positive correlation between the ATF6
protein levels in cultured preadipocytes and plasma lipids
levels in the corresponding individuals. Obviously, human
liver would have been the most preferable tissue for these
types of protein experiments. However, liver biopsy is an
invasive procedure that can cause potentially life-threatening
complications. Therefore, we used adipose biopsies, also
relevant for studies of lipid metabolism.
The Met[67]Val substitution in ATF6 (rs1058405) is a
common variation. Its MAF ranges from 7% in black to 23%
and 29% in Asian and European populations, respectively. It
is an excellent functional candidate as it resides within the
VN8-like domain of ATF6 (supplemental Figure 2). The VN8
domain was identified in the virion protein 16 (VP16)
transcription factor from herpes simplex virus type I and is
required for transcriptional activation and rapid proteasomal
degradation of VP16.14,15 More recently, Thuerauf et al
identified a VN8-like domain in ATF6, which is 75%
identical to the VN8 domain in VP16.12 Analogous to VP16,
the ATF6-VN8 region was found to be critical for transcrip-
tional activity and subsequent degradation of ATF6. Mutating
amino acid 62 and 64 in the ATF6-VN8 region caused a
5-fold reduction in transcriptional activity.12 Our transfection
experiments with mutated ATF6 constructs revealed that the
valine variant at position 67 increases ATF6 transcriptional
activity in cultured cells. Furthermore, ATF6 levels were
increased with the Val allele when compared to the Met allele
construct. According to the dbSNP-database rs1058405 is
possibly a triallelic variant (Met-Val-Leu). The leucine vari-
ant could be a sequencing error as it was originally identified
in a sample size of 4 individuals with validation status
unknown, and we did not detect it in 200 subjects that we
specifically screened for the leucine variant. Nevertheless,
mutating amino acid 67 to leucine further increased ATF6
levels, as well as its targets, Grp78 and Grp94, illustrating the
importance of amino acid 67 for ATF6 transcription activity.
Zeng and colleagues recently elucidated a potential molec-
ular mechanism through which ATF6 can modulate choles-
terol homeostasis.6 In response to glucose starvation, acti-
vated ATF6 can interact with SREBP2 and bind as a
heterodimer to SREs in the promoters of cholesterogenic
genes, eg, the LDL receptor. Bound to SRE, the ATF6-
SREBP2 heterodimer recruits HDAC1, and together they
exert a major inhibitory effect on SREBP2 transcription
activity.6 It is tempting to propose an additional inhibitory
effect on SREBP2 activity attributable to the Met[67]Val
gain-of-function-polymorphism, which would further reduce
the number of LDL receptors that bind and internalize LDL
and VLDL particles, consequently increasing plasma choles-
terol levels. Recently, it has also been demonstrated that
prolonged high glucose conditions induce ER stress and
ATF6 activity.5 These findings both suggest that glucose
levels may present a confounding factor in the genetic
analysis of ATF6. We observed an interaction between the
valine variant and T2DM on plasma TC levels, suggesting
that impaired glucose homeostasis may confound the associ-
ations with ATF6. However, the potential confounding role
of glucose homeostasis and the exact mechanism through
Figure 2. Potency of FLAG-ATF6(1–373)-[67]-methionine, FLAG-
ATF6(1–373)-[67]-valine, and FLAG-ATF6(1–373)-[67]-leucine to
induce luciferase expression in HeLa cells through the GRP78 pro-
moter. HeLa cells were transfected with 1 of the FLAG-ATF6(1–
373) plasmids (1 g). Cells were cotransfected with either pGL2p,
or GRP78-luciferase reporter plasmid (10 g), and CMV--gal (1
g). Each value represents the mean and SEM of 4 independent
transfections from triplicate cultures. *P0.05, #P0.001.
Figure 3. Potency of FLAG-ATF6(1–373)-
[67]-methionine, FLAG-ATF6(1–373)-[67]-
valine, and FLAG-ATF6(1–373)-[67]-
leucine to induce endogenous GRP94
and GRP78 levels. A, HeLa cells, trans-
fected with 1 of the FLAG-ATF6(1–373)
plasmids (1 g), were extracted and an-
alyzed for expression of FLAG-ATF6,
Grp78, Grp94, and GAPDH by Western
blot using specific antiserum antibodies
for FLAG, KDEL (Grp78 and Grp94), and
GAPDH, respectively. B, Quantification
of the blots by densitometry analysis.
Each value represents the mean and
SEM of 4 independent transfections).
*P0.05, #P0.01.
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which the Met[67]Val substitution in ATF6 affects choles-
terol metabolism remains to be addressed in future studies.
Recently, the GWAS data of predominantly population-
based cohorts were analyzed for lipid traits.16 SNP3 was not
significantly associated with LDL-C in this meta-analysis
using an additive model (P0.05). However, as the types of
genes identified in a GWAS naturally depend and reflect the
characteristics of the study samples, it is likely that other
variants and genes will be identified in studies based on CVR.
In our analyses of all samples and the METSIM cohort, the
association signal originated specifically from subjects at
increased cardiovascular risk without T2DM or family his-
tory of T2DM. Notably, although our combined probability
value of both stages indicates a significant overall associa-
tion, the association signal and the proportion of variance
explained by SNP3 were less significant in Sample 4, selected
from the population based METSIM cohort. Furthermore, a
recessive mode of inheritance was suggested throughout the
samples except for Sample 4, as evident by the sign and the
significance of the dominant-deviation term. These differ-
ences may reflect the fact that population-based cohorts are
not optimal for detecting modest effects, particularly those
that are largely recessive. As CVD risk factors are highly
prevalent in the population because of modern lifestyle,
sampling cases from a population-based cohort hampers the
possibilities to collect cases based on the true genetic back-
ground. This environmental “noise” may have resulted in a
limited power to detect the effect of SNP3 in the METSIM
cohort. Therefore, the genetic model and the significance of
SNP3 on cholesterol levels need to be addressed in future
replication studies using large samples ascertained for CVR.
The effect of SNP3 suggest that this SNP alone is not a major
determinant of cholesterol levels, but rather a modifier variant
that influences cholesterol levels. However, the combined effect
of SNP3 and additional risk factors is likely to be more
pronounced, and thus, more easily detectable in study samples
that are enriched for CVD risk factors. This may explain the
consistent association observed in the CVR and FCHL samples
and the lack of association signal in the entire unascertained
METSIM cohort or recent GWAS for lipids.16 As exemplified
by our current study and given the complex architecture of
common diseases, such as CVD, it may be more important to
select replication samples using the specific attributes of the
initial study than the size of the replication sample in general.
In conclusion, our data suggest that the Met[67]Val substitu-
tion in the ATF6-gene is associated with cholesterol levels in
subjects with increased risk to develop CVD. We also demon-
strate that the Met[67]Val substitution is a gain-of-function
polymorphism that increases ATF6 transcriptional activity.
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Online supplemental material for MS#ATVB/2008/180240, entitled “The ATF6-
Met[67]Val substitution is associated with increased plasma cholesterol 
levels”, by Steven Meex et al. 
 
Methods 
Study Participants 
The study design was approved by the ethics committees of the participating centres and all 
subjects gave written informed consent. Clinical characteristics of the study sample are listed in Table 
1. 
Stage 1 study samples 
Sample 1, Dutch CVR (cardiovascular risk). A total of 393 unrelated subjects at increased risk 
for CVD, i.e. with the following risk factors: age 40-70 years and either hypertension (HT), or body 
mass index (BMI) >25 kg/m2 from the Cohort study of Diabetes and Atherosclerosis Maastricht 
(CoDAM) were genotyped. Details of the CoDAM study design are described in detail elsewhere.1 To 
eliminate possible interactions with type 2 diabetes (T2DM)2,3, individuals with T2DM based on an oral 
glucose tolerance test were excluded from this study sample. Lipid lowering drug treatments were 
withheld for 2 weeks before fasting blood sample were taken.  
Sample 2, Dutch FCHL. A total of 195 unrelated probands and spouses from families with an 
established diagnosis of FCHL were genotyped. The FCHL families were recruited through the Lipid 
Clinic of the Utrecht University Hospital (until 1997) and Maastricht University Hospital (1997-2004) as 
described in detail previously.4 Lipid phenotypes were measured as described previously4. Lipid 
lowering drug treatments were withheld for 2 weeks before fasting blood sample were taken. 
Participants were instructed to abstain from alcohol for 72 h and from smoking on the morning of their 
visit to the lipid clinic.  
Stage 2 study samples 
Sample 3, Finnish FCHL. A total of 61 Finnish FCHL families with 715 individuals genotyped 
were recruited in the Helsinki and Turku University Central Hospital, as described in detail previously.5 
Lipid phenotypes were measured as described previously.5 Lipid lowering drug treatments were 
withheld for 4 weeks before fasting blood sample were taken. 
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Finnish population-based cohort, The METSIM (METabolic Syndrome In Men) cohort consists 
of 5,112 male subjects, age 50-70 years, randomly selected from the population of Kuopio in Eastern 
Finland (population 95,000). Recruitment, data collection and phenotypic determinations were 
performed in the University of Kuopio as described previously.6 Each participant underwent an 
evaluation of their disease history, drug treatment, cardiovascular risk factors and an extensive panel 
of lipid, glucose and other metabolic traits. Subjects reimbursed for lipid lowering therapies (n=599) 
were excluded from the analyses. 
Sample 4, Finnish CVR. A total of 1,371 subjects with CVR (cardiovascular risk) were selected 
from the METSIM cohort using the same ascertainment criteria used for the Dutch CVR (Sample 1), 
i.e. either BMI >25 kg/m2 or reimbursed for medication for the treatment of HT. To eliminate possible 
interactions with T2DM, individuals with family history of T2DM and/or T2DM based on an oral glucose 
tolerance test were excluded from this study sample.  
SNP selection and genotyping 
To select SNPs in the ATF6-gene region (193±3kb) for stage 1 genotyping we utilized the 
HapMap CEU population with northern and western Europe ancestry. We used the Haploview 
software7 to select 13 tag SNPs with minor allele frequency (MAF) > 0.1 and r2 threshold of 0.85 
(rs4657101, rs7553368, rs4579731, rs2134697, rs1503815, rs2340721, rs11581364, rs7554023, 
rs10918215, rs7514053, rs10918243, rs13401and rs3795649). In addition, 3 coding SNPs were also 
selected (rs1058405, rs2070150 and rs1135983). The stage 1 genotyping of 16 SNPs was performed 
using the TaqMan 7900HT (Applied Biosystems) in 588 subjects of Samples 1 and 2. We obtained > 
97% success rate for all SNPs. The SNPs rs10918215 and rs7514053 were in complete LD (r2=1) with 
rs13401 and the SNP rs2070150, was in complete LD with rs1135983. Therefore we excluded these 
SNPs, resulting in a total of 13 SNPs analyzed. In stage 2 genotyping the rs1058405 (SNP3) was 
genotyped in 61 Finnish FCHL families (Sample 3) using the pyrosequencing technique on the PSQ 
HS96A platform and in the METSIM cohort using the TaqMan assay. The genotype call rate was 98% 
in Sample 3, and 99% in the METSIM cohort. We replicated 10% of the stage 1 genotypes for SNP3 
using different DNA dilutions from the same individual and two different genotyping techniques, i.e. 
TaqMan and pyrosequencing. Only one of the genotypes did not replicate. All SNPs were in Hardy-
Weinberg equilibrium in all subjects of Sample 1 and 4, as well as in the Dutch and Finnish FCHL 
spouses.  
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Statistical Analyses  
We utilized a two-stage study design, in which all tag-SNPs were first analyzed in stage1. The 
variant that provided the strongest association signal in the stage 1 analyses was further analyzed in a 
combined analysis of both stages. This design was originally introduced by Skol et al. to reduce the 
cost of genotyping while maintaining the overall power of the study.8 Association analysis of the stage 
1 samples with continuous traits (TC, LDL-C and apoB) was performed using PLINK v1.01 software.9 
We tested the genotypic model using multivariate linear regression while including age and sex as 
covariates. The genotypic test is a two degrees of freedom (d.f) test of of an additive ( βˆ add) and a 
dominance-deviation ( βˆ dev) effect. The βˆ dev coefficient is called dominance-deviation as it reflects a 
deviation from an additive effect. A recessive character is suggested when the sign of βˆ dev is 
opposite of βˆ add, and a dominant character is suggested when the signs of both coefficients are in 
the same direction. A full recessive or dominant model is observed when the magnitude of the effects 
is equal adddev ββ ˆˆ = . To avoid violating the assumptions of the test statistics, we estimated empirical 
p-values in the combined analysis of Sample 1 and 2 by combining the χ2 statistics from 20,000 
random permutations of each sample weighted by the proportion of individuals examined in each 
sample.6 Accordingly, the empirical p-value of each SNP was calculated as (R+1)/(20,000+1) where R 
is the number of times the permuted combined statistic was greater than the observed combined 
statistic. Association analysis of the Finnish FCHL families (Sample 3) with residual traits adjusted for 
age and sex was performed using the genotypic model of the family-based association test (FBAT) 
software.10 The genotypic model of FBAT compares all genotypes simultaneously to their null 
expectation in one test with 2 d.f and the test statistic follows a χ2 distribution. The PedCheck 
program11 was used to detect Mendelian errors in the families. All statistical analyses of the METSIM 
cohort were performed using the SPSS 15.0 software. We assessed the effect of SNP3 on continuous 
traits using multivariate linear regression for the genotypic model. Multiplicative interaction with CVR 
and T2DM and/or family history of T2DM was tested by including in the model the genotypes coded as 
0, 1, 2 copy of the Val variant (g); the risk factor (CVR or T2DM) coded as 1 or 0 (r); and their 
interaction term (gr). The combined analysis of stage 1 and 2 and the meta-analysis were performed 
using Fisher’s method for combining P-value with the proportions of the sample sizes as weights.12 
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This statistic follows a chi-square distribution with 2k degrees of freedom, where k is the number of 
independent tests. The weighted Fisher’s χ2 method [CwF = -2wiln(pi)] was calculated in R.2.8.0 as 
follow: w=k*size/sum(size) # where size is the sample size; cwf =-2*sum(w*log(p)); df=2*k ;p.cwf=1 - 
pchisq(chi, df). We performed a meta-analysis of stage 1, Sample 3 and the entire METSIM cohort as 
well as while excluding the subjects with T2DM or family history of T2DM from the METSIM cohort. 
The proportion of variance explained (R2) was calculated using univariate general linear model in 
SPSS 15.0. In the FCHL families (Sample 3), the R2 values were calculated with adjustment for family 
membership as a factor.13 
To test for associations with untyped SNPs within the ATF6 region, we used the Bayesian 
IMputation-Based Association Mapping (BIMBAM) software version 0.99.14  We utilized the phased 
chromosomes of 60 HapMap CEU founders to impute genotypes of 249 SNPs with MAF>5% and 
genotype call rate>95% in the 254kb region on chromosome 1. We only used the subjects of stage 1 
with complete genotype data (n=498) and residual trait (Z-scores) adjusted for age and sex were 
prepared separately in each sample. Ten SNPs failed the first run of imputations (average of 1,000 
imputations), indicated by the standard-error (SE) of the Bayes factor (BF) estimate. The BFs were 
computed using the prior D2 from Servin and Stephens14, averaging over σa = 0.05; 0.1; 0.2; 0.4 and 
σd = σa/4 where σa denotes the prior for the additive effect and σd denotes the prior for the 
dominance-deviation effect. We also used the BFs to compute P-values using 10,000 permutations. 
The posterior-mean-genotypes were used to calculate the average posterior probability of each SNP, 
calculated as the percentage of individuals with >80% posterior probability for calling a genotype 0, 1 
or 2. Only P-values for those 200 SNPs with at least 80% average posterior probability are presented 
in Figure 1 
Cell studies and functional experiments 
Isolation and culture of pre-adipocytes  
Adipose tissue was collected as described previously.15 Following the fat biopsy and 
collagenase treatment, the cell suspension was filtered through 500 µm nylon mesh and spun at 
220×g for 1 min to separate pre-adipocytes from mature adipocytes. Pre-adipocytes were suspended 
in 5 ml DMEM medium containing 10% fetal calf serum (FCS) and 1% glutamine / streptomycine / 
peniciline (GSP) and cultured during 4 passages under standardized conditions. ATF6 protein levels 
were measured by western blot in lysates of cultured primary pre-adipocytes, derived from 11 
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subjects. Clinical characteristics of these subjects at the time of the fat biopsy were as follows: 6 
women/5 men, age 50±12 years, BMI 26.8±2.2 kg/m2, TC 5.7±1.5 mmol/L, LDL-C 4.1±1.7 mmol/L, 
apoB 1.12±0.33 g/L, TG 2.1±1.8 mmol/L. 
 
HeLa cell culture and transfection 
HeLa cells were maintained in DMEM containing 10% fetal calf serum. HeLa cells were 
resuspended at 2.5*106 cells per 400µl of cold Dulbecco’s phosphate-buffered saline and 
electroporated in a 0.4-cm gap electroporation cuvette at 250V and 950 microfarads using a 
GenePulser II Electroporator (Bio-Rad). Cells were then plated at a density of 0.5*106 per 24-mm well 
for luciferase and galactosidase assays, or 1.5*106 per 35-mm well for Western blot experiments. 
Plasmids 
  Cytomegalovirus-Galactosidase: Cytomegalovirus-galactosidase, which is driven by the 
cytomegalovirus promoter and codes for galactosidase, was used to normalize for transfection 
efficiency. 
Flag-ATF6-(1à373[67]-Met/Val/Leu): These Flag-ATF6 constructs are driven by the 
cytomegalovirus promoter, and encode amino acid 1-373 of the ATF6 protein that confer strong 
constitutive transcriptional activity, mimicking all aspects of cleaved endogenous ATF6. All three 
constructs contain a 3xFLAG-epitope and only differ by their amino acid at position 67 (Met, Val or 
Leu). Construction of Flag-ATF6-(1à373[67]-Leucine) has been described previously16. This parent 
vector was used as a template to create Flag-ATF6-(1-373[67]-Methionine) and Flag-ATF6-
(1à373[67]-Valine) by site-directed mutagenesis (QuickChange kit, Stratagene, Inc.) using the 
following primers:  
[67]-Methionine-sense GATTTGGATTTGATGCCTTGGGAGTCAGAC;  
[67]-Methionine-antisense GTCTGACTCCCAAGGCATCAAATCCAAATC;  
[67]-Valine-sense GATTTGGATTTGGTGCCTTGGGAGTCAGAC;  
[67]-Valine-antisense GTCTGACTCCCAAGGCACCAAATCCAAATC.  
Nucleotides in bold were responsible for the desired amino acid substitutions. 
Grp78 promotor(-284à+221)-Luciferase: This construct encodes the GRP78 promoter from -
284 to +221 driving luciferase. It was created by PCR using HeLa genomic DNA as a template and a 
sense primer that begins at base -284 and includes a Kpn1 restriction site and an antisense primer at 
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+221 and includes an Xho1 restriction site. The resulting PCR product was digested with Kpn1 and 
Xho1, creating the GRP78-promoter (-284 to +221), which was ligated into the vector pGL2 
(Promega). 
The pGL2 promoter (catalog number E1631; Promega) contains an SV40 promoter upstream 
of a luciferase reporter gene. 
Reporter assays 
β-galactosidase: 48 hours after transfection, cells were lysed in 500 µl of ice-cold lysis buffer 
(25 mM Gly-Gly, pH 7.8, 15 mM MgSO4, 4 mM EDTA, 0.25% Triton X-100, and 1 mM dithiothreitol). 
Following centrifugation of the cell lysate, 100 µl of supernatant was combined with 500 µl of 
galactosidase buffer (60 mM Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1mM MgSO4, 1 mg/ml 
chlorophenol red-D-galactopyranoside, and 50 mM 2-mercaptoethanol) and after 1h of incubation 
absorbance was measured at 570 nm. 
Luciferase: Following cell lysis and centrifugation as described above, 100µl cell lysate was 
combined with 100 µl of luciferase buffer (the above described lysis buffer containing 45 mM MgSO4, 
0.3 mM D-luciferin, and 3 mM ATP). An Optocompt II luminometer (MGM Instruments, Inc) was used 
to measure light emission of each sample for 10 seconds. Relative luciferase activities were 
determined by dividing luciferase values by β-galactosidase values.  
Western Blotting: Cell cultures were extracted in lysis buffer composed of 20 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml 
leupeptin, and 10 mg/ml aprotinin. After clearing by centrifugation, the protein concentration of the 
lysate was determined. Protein dilutions were prepared with appropriate amount of 2x Laemmli buffer 
and equal amounts of protein from each sample and then fractionated by 10% SDS-PAGE and 
transferred to a polyvinylidene difluoride membrane. Membranes were then probed with ATF6-alpha 
antiserum (Santa Cruz Biotechnology, California), beta-actin antiserum (Biolegend, San Diego), FLAG 
antiserum (F-3165, Sigma), KDEL antiserum (SPA-827,Stessgen Biotechnologies Inc, San Diego, 
CA), or GAPDH (RDI-TRK 5G4-65C; Research Diagnostics Inc, Flanders, NJ). 
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Supplemental Figure legends 
Figure S1 
ATF6 protein from cultured pre-adipocytes as measured by western blot using ATF6-specific 
antiserum antibody. Western blots were quantified by densitometry analysis and ATF6 protein levels 
were normalized to beta-actin (A.U. indicates arbitrary units). Positive correlation with plasma TC (A) 
LDL-C (B) and apoB (C) levels is shown. The Pearson correlations with TC, LDL-C and apoB were 
0.64, 0.72, and 0.76; respectively with corresponding P-values p=0.032, 0.018, and 0.006. 
 
Figure S2 
A. Schematic representation of full-length and cleaved (activated) ATF6.  
B. Detailed representation of the VN8-like region (amino acid 61-68) in ATF6. The Met[67]Val amino-
acid substitution (grey box), is associated with cholesterol levels. 
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Table S1. Clinical characteristics of the study samples 
  N Age TC LDL-C ApoB BMI Glucose SBP DBP Met[67]Val 
Study sample (%female) (mmol/L) (mmol/L) (g/L)  (kg/m2) (mmol/L) (mmHg) (mmHg) (MAF) 
Stage I study samples         
Sample 1 Dutch CVR 393 (30%) 59±7 5.23±0.91 3.34±0.85 1.12±0.24 28±4.04 5.38±0.50 140±20 84±10 0.30 
Sample 2 Dutch FCHL 195 (54%) 51±11 6.06±1.37 4.01±1.22 1.14±0.33 26±3.50 5.11±0.78 133±19 85±12 0.27 
Stage II study samples         
Sample 3 Finnish FCHL 715 (51%) 41±17 6.14±1.45 3.89±1.19 1.12±0.38 26±4.78 5.11±1.50 130±17 81±12 0.24 
Sample 4 Finnish CVR 1,371 (0%) 59±6 5.49±0.96 3.52±0.85 1.10±0.28 29±3.30 5.72±0.50 142±16 90±9 0.31 
Population-based cohort         
METSIM 4,532 (0%) 59±6 5.39±0.96 3.42±0.85 1.06±0.27 27±3.75 5.94±1.17 140±17 88±10 0.31 
Trait values represent the mean ± SEM. BMI, indicates body mass index; SBP, systolic blood pressure and DBP, diastolic blood pressure. 
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Table S2. Association results of ATF6 polymorphisms with TC, LDL-C and apoB levels in stage 1 analyses 
SNP Genotype N MAF TC (mmol/L) Combined LDL-C (mmol/L) Combined ApoB (g/L) Combined 
  I II I II Sample I Sample II P-value Sample I Sample II P-value SampleI Sample II P-value 
SNP 1 C/C 27 12     5.13±0.18 5.98±0.39   3.37±0.16 4.17±0.36   1.14±0.05 1.15±0.10   
rs4657101 A/C 146 57 0.26 0.23 5.31±0.08 6.29±0.18 0.894 3.39±0.08 4.09±0.16 0.834 1.13±0.02 1.18±0.04 0.846 
  A/A 205 106     5.21±0.05 5.93±0.13   3.34±0.05 3.94±0.13   1.12±0.02 1.11±0.03   
SNP 2 C/C 32 19     5.05±0.16 6.19±0.31   3.26±0.16 4.04±0.28   1.09±0.04 1.16±0.07   
rs7553368 T/C 165 72 0.31 0.30 5.28±0.08 5.98±0.16 0.559 3.37±0.08 4.01±0.16 0.861 1.13±0.02 1.13±0.04 0.821 
  T/T 178 87     5.23±0.08 6.06±0.16   3.34±0.05 3.96±0.13   1.11±0.02 1.13±0.04   
SNP 3 G/G 33 20     5.54±0.16 6.71±0.28   3.73±0.16 4.43±0.26   1.24±0.04 1.31±0.07   
rs1058405 A/G 168 58 0.30 0.27 5.21±0.08 5.91±0.18 0.009 3.29±0.05 3.94±0.16 0.008 1.10±0.02 1.11±0.04 0.002 
  A/A 183 103     5.21±0.08 5.96±0.13   3.34±0.05 3.91±0.1   1.12±0.02 1.11±0.03   
SNP 4 T/T 4 1     4.92±0.44 6.55   3.16±0.41 4.77   1.08±0.12 1.29   
rs1135983 C/T 53 23 0.08 0.07 5.21±0.13 6.22±0.28 0.653 3.29±0.10 3.89±0.26 0.697 1.09±0.03 1.12±0.07 0.775 
  C/C 324 155     5.26±0.05 6.01±0.1   3.39±0.05 3.99±0.1   1.13±0.01 1.13±0.03   
SNP 5 G/G 8 2     5.26±0.31 5.98±0.96   3.47±0.28 4.09±0.85   1.07±0.08 1.27±0.23   
rs4579731 A/G 86 39 0.14 0.12 5.26±0.10 5.91±0.21 0.997 3.32±0.08 3.78±0.18 0.900 1.12±0.03 1.10±0.05 0.663 
  A/A 280 135     5.26±0.05 6.06±0.1   3.37±0.05 4.01±0.1   1.13±0.01 1.14±0.03   
SNP 6 C/C 24 8     5.02±0.18 5.96±0.49   3.19±0.18 3.94±0.44   1.04±0.05 1.11±0.13   
rs2134697 T/C 139 75 0.25 0.25 5.23±0.08 5.8±0.16 0.270 3.32±0.08 3.81±0.16 0.348 1.11±0.02 1.10±0.04 0.133 
  T/T 216 100     5.28±0.05 6.27±0.13   3.39±0.05 4.17±0.13   1.14±0.02 1.17±0.03   
SNP 7 T/T 6 3     4.51±0.36 6.22±0.78   2.72±0.34 3.86±0.7   0.96±0.10 1.20±0.23   
rs1503815 C/T 70 40 0.11 0.13 5.26±0.10 5.72±0.21 0.071 3.37±0.10 3.89±0.18 0.114 1.12±0.03 1.09±0.05 0.157 
  C/C 302 139     5.26±0.05 6.14±0.1   3.37±0.05 4.01±0.1   1.13±0.01 1.15±0.03   
SNP 8 A/A 44 19     5.00±0.13 5.8±0.31   3.11±0.13 3.89±0.26   1.04±0.04 1.07±0.08   
rs2340721 C/A 171 86 0.34 0.34 5.23±0.08 5.93±0.16 0.063 3.37±0.05 3.91±0.13 0.045 1.12±0.02 1.12±0.04 0.008 
  C/C 167 80     5.28±0.08 6.24±0.16   3.42±0.05 4.14±0.13   1.14±0.02 1.18±0.04   
SNP 9 T/T 53 32     5.21±0.13 6.06±0.23   3.39±0.10 3.96±0.21   1.13±0.03 1.14±0.06   
rs11581364 G/T 171 75 0.37 0.39 5.26±0.08 5.98±0.16 0.977 3.34±0.05 3.94±0.13 0.750 1.12±0.02 1.10±0.04 0.727 
  G/G 155 70     5.21±0.08 6.14±0.16   3.32±0.08 4.09±0.16   1.11±0.02 1.18±0.04   
SNP 10 G/G 10 7     4.95±0.28 6.19±0.52   3.16±0.26 4.56±0.44   1.11±0.07 1.19±0.12   
rs7554023 A/G 120 47 0.19 0.17 5.34±0.08 6.11±0.21 0.606 3.47±0.08 4.01±0.18 0.417 1.15±0.02 1.16±0.05 0.879 
  A/A 246 123     5.21±0.05 5.98±0.13   3.29±0.05 3.94±0.1   1.11±0.01 1.12±0.03   
SNP 11 C/C 42 24     5.41±0.13 6.58±0.26   3.57±0.13 4.33±0.23   1.20±0.04 1.25±0.07   
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rs10918243 T/C 183 75 0.35 0.35 5.26±0.05 5.93±0.16 0.033 3.37±0.05 3.89±0.13 0.054 1.12±0.02 1.11±0.04 0.008 
  T/T 153 80     5.15±0.08 6.01±0.16   3.26±0.08 4.01±0.13   1.10±0.02 1.13±0.04   
SNP 12 G/G 21 14     5.10±0.18 5.75±0.36   3.19±0.18 3.89±0.34   1.07±0.05 1.06±0.09   
rs13401 A/G 144 65 0.25 0.25 5.18±0.08 6.01±0.18 0.390 3.26±0.08 3.91±0.16 0.390 1.10±0.02 1.12±0.04 0.202 
  A/A 210 110     5.28±0.05 6.14±0.13   3.42±0.05 4.09±0.13   1.14±0.02 1.15±0.03   
SNP 13 T/T 57 33     5.18±0.13 6.11±0.23   3.39±0.10 4.07±0.21   1.13±0.03 1.17±0.06   
rs3795649 C/T 186 81 0.40 0.40 5.23±0.08 5.93±0.16 0.856 3.32±0.05 4.01±0.13 0.955 1.12±0.02 1.12±0.04 0.960 
  C/C 134 65     5.26±0.08 6.14±0.16   3.37±0.08 3.99±0.16   1.12±0.02 1.15±0.04   
Trait values represent the marginal mean evaluated at the average age and sex ±SEM  
The P-values represent the results of the combined analysis of stage 1 and 2, as described in Supplementary methods. 
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Table S3. Descriptive statistics of glucose traits for the METSIM cohort by family history of T2DM  
Trait 
FHDM* 
n=2,099 
Non-FHDM 
n=2,432 
P value† 
 
Fasting plasma glucose (mmol/l) 6.08±0.03 5.8±0.02 1.52E-17 
Glucose 120min (mmol/l) 6.71±0.06 6.34±0.05 2.45E-06 
Fasting serum insulin (mU/l) 10.25±0.34 8.58±0.14 8.17E-07 
Insulin 120min(mU/l) 55.9±1.28 52.6±1.15 1.22E-03 
Glucose AUC (mmol/l * min) 932±4.94 903±3.82 2.04E-06 
Insulin resistance index (HOMA) 3.03±0.12 2.34±0.05 3.82E-10 
Insulin sensitivity index (QUICKI)   0.63±0.003 0.65±0.003 6.69E-10 
Trait values represent the mean ± SEM. AUC, indicates area under the glucose curve attained during 
an oral glucose tolerance test; HOMA, Homeostatic model assessment and QUICKI, quantitative insulin 
sensitivity check index. 
*FHDM, indicates subjects with family history of diabetes.  
†The P value represents the results obtained by independent t-tests with log transformed values. 
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Figure S1 
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Figure S2  
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